The Patent Finder

Cnpharm Co., Ltd.

9 patents currently held · Updated Nov 22, 2026
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Mar 2035
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Jan 2, 2027
    The maintenance fee for Cationic polyphosphazene compound, polyphosphazenes-drug conjugate compound and method for preparing same (US 10,336,867) comes due Jan 2, 2027. Unpaid by Jul 2, 2027, it lapses early.
  • 1 fee due Aug 27, 2027
    The maintenance fee for Cationic polyphosphazene compound, polyphosphazenes-drug conjugate compound and method for preparing same (US 11,912,829) comes due Aug 27, 2027. Unpaid by Feb 28, 2028, it lapses early.
  • 2 fees due Sep 10 to 17, 2027 · next Sep 10
  • 1 fee due Oct 30, 2027
    The maintenance fee for Metal (HYDR)OXIDE Composite Comprising Poorly Soluble Drug, Method for Manufacturing Same, and Pharmaceutical Composition Comprising Same (US 11,969,440) comes due Oct 30, 2027. Unpaid by May 1, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Showing 1 to 9 of 9

Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 10,584,214Cationic polyphosphazene compound, polyphosphazenes-drug conjugate compound and method for preparing same
In force
 · USPTO record
In forceUSPTO record
US 10,590,243Cationic polyphosphazene compound, polyphosphazenes-drug conjugate compound and method for preparing same
In force
 · USPTO record
In forceUSPTO record
US 11,180,615Cationic polyphosphazene compound, polyphosphazenes-drug conjugate compound and method for preparing same
In force
 · USPTO record
In forceUSPTO record
US 11,912,829Cationic polyphosphazene compound, polyphosphazenes-drug conjugate compound and method for preparing same
In force
 · USPTO record
In forceUSPTO record
US 10,336,867Cationic polyphosphazene compound, polyphosphazenes-drug conjugate compound and method for preparing same
In force
 · USPTO record
In forceUSPTO record
US 12,409,229Synthesizing drug-organic-acid-anhydride conjugates without using coupling reagent
In force
 · USPTO record
In forceUSPTO record
US 11,969,440Metal (HYDR)OXIDE Composite Comprising Poorly Soluble Drug, Method for Manufacturing Same, and Pharmaceutical Composition Comprising Same
In force
 · Medium confidence
In forceMedium confidence
US 12,297,213Metal hydroxide complex comprising modified multilayer hydroxide structure comprising active ingredient and method of manufacturing same
In force
 · USPTO record
In forceUSPTO record
US 12,419,961Docetaxel-aconitic anhydride conjugate exhibiting anti-tumor activity without in vivo toxicity
In force
 · USPTO record
In forceUSPTO record
Also on record, not counted in the 9: 1 lapsed for an unpaid fee · 2 ended at full term. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

3 pending · 5 no status recorded

Showing 1 to 8 of 8, newest filing first. An application has no patent term. A term is computed when and if it grants, and appears on that patent's own page. Where no title is shown, the bulk publication record carries none and this site holds no USPTO file history for that application.

ApplicationTitleFiledStatus
19/216,544May 22, 2025No status recorded
18/649,055Metal (HYDR) Oxide Composite Comprising Poorly Soluble Drug, Method for Manufacturing Same, and Pharmaceutical Composition Comprising SameApr 29, 2024Pending
18/587,826Novel Cationic Polyphosphazene Compound, Polyphosphazenes-Drug Conjugate Compound and Method for Preparing SameFeb 26, 2024Pending
18/844,666Mar 8, 2023No status recorded
18/844,613Pharmaceutical Composition Containing Docetaxel or Pharmaceutically Acceptable Salt Thereof and Preparation Method ThereforDec 20, 2022Pending
17/320,592May 14, 2021No status recorded
17/428,111Apr 23, 2021No status recorded
13/995,557Dec 16, 2011No status recorded
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 22, 2026 · includes USPTO assignment data published Nov 21, 2026, status data published Nov 22, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited